What is Zacks Research’s Forecast for UTHR FY2024 Earnings?

United Therapeutics Co. (NASDAQ:UTHR) – Stock analysts at Zacks Research upped their FY2024 earnings per share estimates for United Therapeutics in a research note issued on Tuesday, November 19th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings of $24.45 per share for the year, up from their prior estimate of $23.30. The consensus estimate for United Therapeutics’ current full-year earnings is $25.10 per share. Zacks Research also issued estimates for United Therapeutics’ Q1 2025 earnings at $6.93 EPS, Q2 2025 earnings at $6.63 EPS and Q2 2026 earnings at $6.47 EPS.

Other equities analysts also recently issued reports about the company. Bank of America reduced their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. TD Cowen upped their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Wells Fargo & Company boosted their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Stock Up 0.8 %

Shares of UTHR stock opened at $367.36 on Thursday. The business has a 50 day moving average of $364.39 and a two-hundred day moving average of $330.59. United Therapeutics has a 52 week low of $208.62 and a 52 week high of $417.82. The company has a market cap of $16.40 billion, a P/E ratio of 16.13, a PEG ratio of 1.05 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period last year, the firm earned $5.38 earnings per share.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 15,000 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $407.32, for a total transaction of $6,109,800.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. This trade represents a 67.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,796 shares of company stock valued at $40,936,370 over the last quarter. Corporate insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently bought and sold shares of the company. ClariVest Asset Management LLC raised its holdings in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares during the period. USA Financial Formulas bought a new position in United Therapeutics in the third quarter valued at $33,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics in the 3rd quarter valued at about $33,000. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics in the 2nd quarter valued at about $30,000. Finally, Innealta Capital LLC bought a new position in shares of United Therapeutics in the 2nd quarter valued at about $33,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.